Femasys Inc. Common Stock

FEMY

Femasys Inc. (FEMY) is a healthcare company focused on developing and commercializing innovative products for women's health. The company's offerings include solutions for fertility preservation, endometrial sampling, and other gynecological procedures, aiming to provide less invasive and more effective treatment options for women's reproductive health.

$3.01 -0.04 (-1.31%)
đźš« Femasys Inc. Common Stock does not pay dividends

Company News

Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
GlobeNewswire Inc. • Na • May 13, 2026

Femasys Inc. (NASDAQ: FEMY) announced CE Mark approval for its FemHSG™ Catheter, designed to support fertility diagnosis procedures when used with the FemVue device. The approval expands the company's fertility portfolio in Europe through commercial partners. The catheter features a small-profile design to accommodate varying uterine cavity siz...

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
GlobeNewswire Inc. • Na • January 13, 2026

Femasys Inc. announced a partnership with Refuah Health Center to expand access to FemaSeed, its intratubal insemination product, as a first-line infertility treatment in community-based care settings. The partnership aims to strengthen Femasys' commercial footprint and accelerate adoption of FemaSeed, which has demonstrated over double the pregn...

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
GlobeNewswire Inc. • Kathy Lee-Sepsick • October 16, 2025

Femasys will showcase its FemaSeed Intratubal Insemination technology at the ASRM 2025 Scientific Congress, highlighting a fertility solution that offers higher pregnancy rates compared to traditional intrauterine insemination (IUI).

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
GlobeNewswire Inc. • Kathy Lee-Sepsick • September 11, 2025

Femasys introduces a new FemSperm Insemination Prep Kit to enable gynecologists to perform FemaSeed Intratubal Insemination, aiming to make fertility treatments more accessible and provide an alternative to IVF.

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering
GlobeNewswire Inc. • Femasys Inc. • August 26, 2025

Femasys Inc. announced a public offering of up to 22,184,586 shares of common stock and warrants, expecting to raise approximately $8.0 million to fund commercial expansion, product development, and corporate purposes.

Related Companies